Back to Search Start Over

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan.

Authors :
Ryuge S
Jiang SX
Wada M
Katono K
Iwasaki M
Takakura A
Otani S
Kimura Y
Fukui T
Yokoba M
Kubota M
Katagiri M
Hayakawa K
Masuda N
Source :
Drug design, development and therapy [Drug Des Devel Ther] 2009 Sep 21; Vol. 3, pp. 213-7. Date of Electronic Publication: 2009 Sep 21.
Publication Year :
2009

Abstract

Large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon variant of non-small cell lung cancer. Since the biological characteristics of LCNEC are similar to those of small cell lung cancer, LCNEC is usually treated with chemotherapy regimens used for small cell lung cancer. However, the outcomes are usually dismal. Here, we report a patient with LCNEC (a metastasis to the brain). After whole brain irradiation, he received a combination of amrubicin and irinotecan chemotherapy, and has been relapse-free for two years. This treatment regimen may be beneficial for patients with advanced LCNEC.

Details

Language :
English
ISSN :
1177-8881
Volume :
3
Database :
MEDLINE
Journal :
Drug design, development and therapy
Publication Type :
Academic Journal
Accession number :
19920936
Full Text :
https://doi.org/10.2147/dddt.s6423